\n \n\n \n \n \n \n MORU\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n19 July 2019
\n \n \n \nA large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.
\n \n\n \n \n\n \n\n \n \n \n \n MOCRU\n \n \n \n \n MORU\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n17 July 2019
\n \n \n \nMedical Action Myanmar and MOCRU health teams identified a number of children with rickets in remote areas of Myanmar. MOCRU director Frank Smithuis presented the findings of clinical screening to the Minister of Health, alongside treatment results and a plan for a large survey to investigate the prevalence of vitamin D deficiency and its underlying causes.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n2 July 2019
\n \n \n \nNew research by Makoto Saito and colleagues at SMRU found that a longer follow-up is required to assess antimalarial drug efficacy in pregnant women. This was found across all drugs assessed in low malaria transmission settings. The report\u2019s authors have called for guidelines specifically for pregnant women and further investigation of optimal follow-up periods in high malaria transmission settings.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n28 June 2019
\n \n \n \nIDDO\u2019s visceral leishmaniasis (VL) collaboration is working on two new projects looking at the treatment of VL. The first is a systematic review of the literature on design and analysis of antileishmanial clinical efficacy studies, and the second is a systematic review of published studies to estimate the baseline risk of serious adverse events and mortality in patients treated with antileishmanial therapies.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n14 June 2019
\n \n \n \nWWARN Researcher Debashish Das has been involved in clinical research in various settings in Asia and Africa with the Mahidol-Oxford Tropical Medicine Research Unit (MORU) and M\u00e9decins Sans Fronti\u00e8res (MSF). His research efforts focus on investigating antimalarial drug resistance and finding treatment solutions for young children
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n12 June 2019
\n \n \n \nA ground-breaking study in Bangladesh co-lead by MORU has found that using data from mobile phone networks to track the movement of people across the country can help predict where outbreaks of diseases such as malaria are likely to occur, enabling health authorities to take preventative measures.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n5 June 2019
\n \n \n \nWWARN\u2019s Clinical Scientific Group have published research in BMC Medical Research Methodology comparing different statistical approaches for deriving cumulative estimates of drug efficacy from clinical studies. Results indicate that the Cumulative Incidence Function (CIF) approach should be considered as an alternative to the widely used Kaplan-Meier method for calculating efficacy estimates in high transmission areas.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n24 May 2019
\n \n \n \nAvni Gupta, Communications Officer for AfOx, talks about the work of this university-wide initiative \u2013 which brings the University\u2019s long-standing multi-disciplinary engagement with Africa under one platform
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n17 May 2019
\n \n \n \nIDDO Ebola Data Platform, a pioneering collaboration in Ebola and emerging infections, has today appointed nine members for its first Data Access Committee, overseen and chaired by TDR, the Special Programme for Research and Training in Tropical Diseases, hosted at WHO.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n7 May 2019
\n \n \n \nRift Valley Fever, one of WHO priority diseases, causes abortion and malformation in livestock, as well as occasionally severe symptoms in humans. George Warimwe and colleagues at KWTRP are developing a vaccine suitable for both humans and livestock. This cross-species approach, known as \u201cOne Health\u201d, might in the long term accelerate the design and development of vaccines, protecting human health and biodiversity too.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2019
\n \n \n \nThe attainment of Universal Health Coverage (UHC) is a policy priority at both global and national levels. The Sustainable Development Goals underscore the importance of health and wellbeing for all with three main objectives: equity in access to health services, access to quality health services, and protection from financial risk. In Kenya, although the government has installed UHC as a policy priority, it is still marred in misconstruction and often reduced to health financing. Researchers at KEMRI-Wellcome tracked Kenya\u2019s progress towards UHC between 2003 and 2014 and set out recommendations to support policy makers in designing a body of UHC policy.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2019
\n \n \n \nMalaria is a leading cause of death and illness around the world. Over 200 million cases are reported every year, and more than 400 000 people die. More than 90% of cases are reported in sub-Saharan Africa. Scientists have spent decades searching for an effective vaccine. Hence the recent excitement when Malawi\u2019s government announced it had launched a pilot programme for the world\u2019s first malaria vaccine, RTS,S (also known as Mosquirix\u00a9), produced by the pharmaceutical company, GSK. It\u2019s the first vaccine to demonstrate significant reduction in malaria in children. The Conversation Africa\u2019s Ina Skosana asked immunologist Faith Osier about RTS,S.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Publication\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n25 April 2019
\n \n \n \nIncreased funding is needed to eliminate malaria across 22 Asia-Pacific countries and save an estimated 400,000 lives, according to research published in a new collection of studies on Wellcome Open Research.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n3 April 2019
\n \n \n \nHow do you go about building all the skills you need at the start of your research career? Cherry Lim from our MORU unit in Bangkok, Thailand, was lucky to find a good mentor who guided her through this journey, but her own ceaseless curiosity and excitement about research were also important.
\n \n\n \n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n26 March 2019
\n \n \n \nRob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple Artemisinin Combination Therapies to the All-Party Parliamentary Group on Malaria & NTDs on March 19th in Westminster at the Houses of Parliament.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n26 March 2019
\n \n \n \nA global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n12 March 2019
\n \n \n \nIn an article published in Malaria Journal, members of the WWARN Molecular Scientific and Informatics Group describe the development of WWARN\u2019s ACT Partner Drug Molecular Surveyor. Launched in 2015, this online mapping tool supports the malaria community to track over nearly 20 years the prevalence of the molecular markers that are associated with antimalarial drug resistance.
\n \n\n \n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n6 March 2019
\n \n \n \nGlobal efforts to fight malaria have hit a plateau and new tools are needed to achieve global goals. In this context, a consortium led by the Barcelona Institute for Global Health was awarded $25.3m from Unitaid (unitaid.org) to evaluate mass drug administration of ivermectin to humans and livestock in Tanzania and Mozambique, to kill the mosquitoes that transmit malaria. KWTRP Marta Maia will contribute as lead entomologist to BOHEMIA.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n6 March 2019
\n \n \n \nThanks to an AfOx Travel Grant, Sarah Hill and Nuno Faria from Oxford Department of Zoology travelled to Luanda, Angola, to sequence viruses that cause severe disease. The first genomes of Zika virus detected in patients in Angola were thus sequenced. This method can help reveal the \u2018family tree\u2019 of viruses and better understand how viruses spread across the world. The researchers have now started to sequence additional viral genomes, from dengue and yellow fever, for similar studies on these viruses.
\n \n\n \n \n\n \n\n \n \n \n \n OCGHR\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n6 March 2019
\n \n \n \nPaul Sondo, molecular parasitologist from the Clinical Research Unit of Nanora in Burkina Faso, spent the last 12 months with WWARN as a recipient of the Clinical Research and Development Fellowship. He tells us about his experience as a CRDF Fellow and how it is starting to impact on his clinical research back at the Clinical Research Unit of Nanora.
\n \n\n \n \n